Trial Profile
A Prospective, Multi-center, Cohort Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Therapy in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B; Liver cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 02 Feb 2021 Status changed from active, no longer recruiting to completed.
- 13 Nov 2020 Planned primary completion date changed from 2 Dec 2020 to 8 Jan 2021.
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases